|
1
|
Chao J, Zhao S and Sun H:
Dedifferentiation of hepatocellular carcinoma: Molecular mechanisms
and therapeutic implications. Am J Transl Res. 12:2099–2109.
2020.PubMed/NCBI
|
|
2
|
Garin E, Palard X and Rolland Y:
Personalised dosimetry in radioembolisation for HCC: Impact on
clinical outcome and on trial design. Cancers (Basel). 12:15572020.
View Article : Google Scholar
|
|
3
|
Tellapuri S, Sutphin PD, Beg MS, Singal AG
and Kalva SP: Staging systems of hepatocellular carcinoma: A
review. Indian J Gastroenterol. 37:481–491. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glantzounis GK, Paliouras A, Stylianidi
MC, Milionis H, Tzimas P, Roukos D, Pentheroudakis G and Felekouras
E: The role of liver resection in the management of intermediate
and advanced stage hepatocellular carcinoma. A systematic review.
Eur J Surg Oncol. 44:195–208. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lai HC, Lee MS, Lin C, Lin KT, Huang YH,
Wong CS, Chan SM and Wu ZF: Propofol-based total intravenous
anaesthesia is associated with better survival than desflurane
anaesthesia in hepatectomy for hepatocellular carcinoma: A
retrospective cohort study. Br J Anaesth. 123:151–160. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang H, Benzonana LL, Zhao H, Watts HR,
Perry NJ, Bevan C, Brown R and Ma D: Prostate cancer cell
malignancy via modulation of HIF-1α pathway with isoflurane and
propofol alone and in combination. Br J Cancer. 111:1338–1349.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang W and Shao X: Isoflurane promotes
non-small cell lung cancer malignancy by activating the
Akt-mammalian target of rapamycin (mTOR) signaling pathway. Med Sci
Monit. 22:4644–4650. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Meier A, Gross ETE, Schilling JM, Seelige
R, Jung Y, Santosa E, Searles S, Lin T, Tu XM, Patel HH and Bui JD:
Isoflurane impacts murine melanoma growth in a sex-specific,
immune-dependent manner: A brief report. Anesth Analg.
126:1910–1913. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hu J, Hu J, Jiao H and Li Q: Anesthetic
effects of isoflurane and the molecular mechanism underlying
isoflurane-inhibited aggressiveness of hepatic carcinoma. Mol Med
Rep. 18:184–192. 2018.PubMed/NCBI
|
|
10
|
Seeler JS and Dejean A: SUMO and the
robustness of cancer. Nat Rev Cancer. 17:184–197. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Flotho A and Melchior F: Sumoylation: A
regulatory protein modification in health and disease. Annu Rev
Biochem. 82:357–385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Geiss-Friedlander R and Melchior F:
Concepts in sumoylation: A decade on. Nat Rev Mol Cell Biol.
8:947–956. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Henley JM, Craig TJ and Wilkinson KA:
Neuronal SUMOylation: Mechanisms, physiology, and roles in neuronal
dysfunction. Physiol Rev. 94:1249–1285. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang SC and Ding JL: Ubiquitination and
SUMOylation in the chronic inflammatory tumor microenvironment.
Biochim Biophys Acta Rev Cancer. 1870:165–175. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qiu G, Jin Z, Chen X and Huang J:
Interpretation of guidelines for the diagnosis and treatment of
primary liver cancer (2019 edition) in China. Glob Health Med.
2:306–311. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pang Y, Kartsonaki C, Turnbull I, Guo Y,
Chen Y, Clarke R, Bian Z, Bragg F, Millwood IY, Yang L, et al:
Adiposity in relation to risks of fatty liver, cirrhosis and liver
cancer: A prospective study of 0.5 million Chinese adults. Sci Rep.
9:7852019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McCarty TR, Echouffo-Tcheugui JB, Lange A,
Haque L and Njei B: Impact of bariatric surgery on outcomes of
patients with nonalcoholic fatty liver disease: A nationwide
inpatient sample analysis, 2004–2012. Surg Obes Relat Dis.
14:74–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pinto RZ, Maher CG, Ferreira ML, Ferreira
PH, Hancock M, Oliveira VC, McLachlan AJ and Koes B: Drugs for
relief of pain in patients with sciatica: Systematic review and
meta-analysis. BMJ. 344:e4972012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Komaki Y, Komaki F, Micic D, Ido A and
Sakuraba A: Risk of colorectal cancer in chronic liver diseases: A
systematic review and meta-analysis. Gastrointest Endosc.
86:93–104.e5. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Antipass A, Austin A, Awad S, Hughes D and
Idris I: Evaluation of liver function tests and risk score
assessment to screen patients for significant liver disease prior
to bariatric and metabolic surgery. Obes Surg. 30:2840–2843. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ikuta S, Tanimura K, Yasui C, Aihara T,
Yoshie H, Iida H, Beppu N, Kurimoto A, Yanagi H, Mitsunobu M and
Yamanaka N: Chronic liver disease increases the risk of
linezolid-related thrombocytopenia in methicillin-resistant
Staphylococcus aureus-infected patients after digestive surgery. J
Infect Chemother. 17:388–391. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Esser T, Keilhoff G and Ebmeyer U:
Anesthesia specific differences in a cardio-pulmonary resuscitation
rat model; halothane versus sevoflurane. Brain Res. 1652:144–150.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dugan CM, Fullerton AM, Roth RA and Ganey
PE: Natural killer cells mediate severe liver injury in a murine
model of halothane hepatitis. Toxicol Sci. 120:507–518. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yin H, Cheng L, Langenbach R and Ju C:
Prostaglandin I(2) and E(2) mediate the protective effects of
cyclooxygenase-2 in a mouse model of immune-mediated liver injury.
Hepatology. 45:159–169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhu Y, Xiao X, Li G, Bu J, Zhou W and Zhou
S: Isoflurane anesthesia induces liver injury by regulating the
expression of insulin-like growth factor 1. Exp Ther Med.
13:1608–1613. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng D, Wang Y, Xu Y, Luo Q, Lan B and Xu
L: Interleukin 10 deficiency exacerbates halothane induced liver
injury by increasing interleukin 8 expression and neutrophil
infiltration. Biochem Pharmacol. 77:277–284. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Delgado TC, Lopitz-Otsoa F and
Martínez-Chantar ML: Post-translational modifiers of liver kinase
B1/serine/threonine kinase 11 in hepatocellular carcinoma. J
Hepatocell Carcinoma. 6:85–91. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jin ZL, Pei H, Xu YH, Yu J and Deng T: The
SUMO-specific protease SENP5 controls DNA damage response and
promotes tumorigenesis in hepatocellular carcinoma. Eur Rev Med
Pharmacol Sci. 20:3566–3573. 2016.PubMed/NCBI
|
|
29
|
Kim DH, Kwon S, Byun S, Xiao Z, Park S, Wu
SY, Chiang CM, Kemper B and Kemper JK: Critical role of
RanBP2-mediated SUMOylation of small heterodimer partner in
maintaining bile acid homeostasis. Nat Commun. 7:121792016.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xia W, Tian H, Cai X, Kong H, Fu W, Xing
W, Wang Y, Zou M, Hu Y and Xu D: Inhibition of SUMO-specific
protease 1 induces apoptosis of astroglioma cells by regulating
NF-κB/Akt pathways. Gene. 595:175–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lin CH, Liu SY and Lee EH: SUMO
modification of Akt regulates global SUMOylation and substrate
SUMOylation specificity through Akt phosphorylation of Ubc9 and
SUMO1. Oncogene. 35:595–607. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Risso G, Pelisch F, Pozzi B, Mammi P,
Blaustein M, Colman-Lerner A and Srebrow A: Modification of Akt by
SUMO conjugation regulates alternative splicing and cell cycle.
Cell Cycle. 12:3165–3174. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carbia-Nagashima A, Gerez J, Perez-Castro
C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F and Arzt E:
RSUME, a small RWD-containing protein, enhances SUMO conjugation
and stabilizes HIF-1alpha during hypoxia. Cell. 131:309–323. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wei F, Schöler HR and Atchison ML:
Sumoylation of Oct4 enhances its stability, DNA binding, and
transactivation. J Biol Chem. 282:21551–21560. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Xu Y, Li J, Zuo Y, Deng J, Wang LS and
Chen GQ: SUMO-specific protease 1 regulates the in vitro and in
vivo growth of colon cancer cells with the upregulated expression
of CDK inhibitors. Cancer Lett. 309:78–84. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ge H, Du J, Xu J, Meng X, Tian J, Yang J
and Liang H: SUMOylation of HSP27 by small ubiquitin-like modifier
2/3 promotes proliferation and invasion of hepatocellular carcinoma
cells. Cancer Biol Ther. 18:552–559. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Knowles BB, Howe CC and Aden DP: Human
hepatocellular carcinoma cell lines secrete the major plasma
proteins and hepatitis B surface antigen. Science. 209:497–499.
1980. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Knasmuller S, Parzefall W, Sanyal R, Ecker
S, Schwab C, Uhl M, Mersch-Sundermann V, Williamson G, Hietsch G,
Langer T, et al: Use of metabolically competent human hepatoma
cells for the detection of mutagens and antimutagens. Mutat Res.
402:185–202. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Qiu GH, Xie X, Xu F, Shi X, Wang Y and
Deng L: Distinctive pharmacological differences between liver
cancer cell lines HepG2 and Hep3B. Cytotechnology. 67:1–12. 2015.
View Article : Google Scholar : PubMed/NCBI
|
